Browse the evidence

Semaglutide (a GLP-1RA) produces significant weight loss (10-12.5%) and improves cardiometabolic risk factors, making it more effective than older pharmacotherapies like Phentermine-Topiramate and Orlistat.

Semaglutide is a highly effective weekly injection for weight loss, averaging 10-12% loss in clinical trials. It is more effective than older drugs like Orlistat or Phentermine-Topiramate and also improves heart health markers. It requires weekly injections and titration to manage side effects.

Maintaining a higher proportional energy intake from protein (by limiting discretionary foods) is associated with lower total energy intake and better 12-month weight loss maintenance, whereas diluting protein with high fat/carbohydrate leads to increased energy intake and weight regain via the protein leverage mechanism.

To maintain weight loss, prioritize foods that keep your protein percentage high relative to fats and carbs. Avoid 'discretionary' foods (sweets, processed snacks) which dilute protein concentration and trigger overeating. You don't necessarily need to increase total protein grams, but you must increase its proportion in your diet by reducing low-protein energy sources.

GLP-1 receptor agonists (semaglutide 2.4 mg weekly) significantly improve pain and function in patients with obesity and moderate-to-severe knee osteoarthritis, achieving clinical benefits comparable to or exceeding standard therapies like NSAIDs and physical therapy.

If you have knee osteoarthritis and a BMI over 30, GLP-1 medications like semaglutide (2.4 mg weekly) can significantly reduce pain and improve function, potentially delaying or avoiding surgery. This works not just by helping you lose weight, but by directly reducing inflammation in the joint. Current guidelines suggest aiming for more than 7-10% weight loss for maximum benefit, which these drugs help achieve more effectively than lifestyle changes alone for many people.

Once-weekly subcutaneous semaglutide 2.4 mg combined with diet and exercise reverses prediabetes in approximately 80% of patients with obesity, significantly outperforming diet and exercise alone (12% reversal rate).

If you have obesity and prediabetes, adding once-weekly semaglutide 2.4 mg to your diet and exercise plan significantly increases your chances of reversing prediabetes (from 12% to 80%). This treatment also lowers BMI by ~14% and reduces cardiovascular risks. It requires weekly injections and ongoing lifestyle efforts, as stopping the drug may lead to weight regain and return of prediabetes.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce significant weight loss (14.9%–20.9%) and improve fertility in obese individuals, particularly those with PCOS, by acting on hypothalamic and brainstem regions to suppress appetite and stimulate GnRH/LH release.

GLP-1 agonists like semaglutide and tirzepatide are highly effective for significant weight loss and can improve fertility in obese individuals, especially those with PCOS. However, they come with high rates of gastrointestinal side effects and weight regain upon discontinuation. They should be used under medical supervision, with careful attention to dosing and long-term management strategies.

Strategies to minimize muscle loss during GLP-1 therapy include increasing protein intake to ≥1.2 g/kg/day and engaging in resistance training 2-3 times per week.

To keep your muscles while losing weight on these drugs, eat at least 1.2 grams of protein per kilogram of your body weight every day. Also, lift weights or do resistance exercises 2-3 times a week. This combination helps protect your strength and metabolic rate.

Combining GLP-1 receptor agonists with structured exercise (specifically resistance training) mitigates the loss of lean body mass associated with pharmacological weight loss, whereas GLP-1 agonists alone result in significant lean mass loss.

If you are on a GLP-1 medication like semaglutide or tirzepatide, you must incorporate resistance training (2-3 times per week) into your routine. The medication will cause you to lose muscle along with fat (up to 40% of weight loss). Resistance training preserves this muscle, maintaining your metabolism and strength. Combine this with moderate aerobic activity (150 mins/week) and adequate protein intake for the best long-term results.

Weekly tirzepatide injections combined with dietician support reduce OSA severity by approximately 50% in obese patients with moderate to severe OSA.

If you are obese and have moderate to severe sleep apnea, ask your doctor about tirzepatide. This weekly injection, combined with dietary support, has been shown to cut your apnea severity in half. It is FDA-cleared for this use and may improve your blood pressure and sleep quality, though you should expect some mild stomach issues initially.

Melanocortin-4 receptor (MC4R) agonists significantly reduce body weight, BMI, and hunger scores in patients with obesity, including those with rare genetic syndromes.

If you have obesity, particularly if it is linked to a rare genetic condition, MC4R agonist drugs like setmelanotide can significantly reduce your body weight, BMI, and hunger. These drugs work by activating receptors in your brain that control satiety and energy expenditure. Treatment involves daily subcutaneous injections, with doses adjusted based on your age and how well you tolerate the medication. While lifestyle changes are important, they often lead to modest and unsustainable weight loss, making these drugs a valuable option for those who struggle with conventional methods.

GLP-1 receptor agonists reduce food intake, increase satiety, delay gastric emptying, and improve glucose tolerance, leading to weight loss in humans.

GLP-1 receptor agonists are a proven, FDA-approved treatment for obesity and type 2 diabetes. They work by reducing appetite and improving metabolic function. Consult a healthcare provider to see if this treatment is appropriate for you.

Orforglipron 45 mg significantly reduces BMI, body weight, waist circumference, and HbA1c in patients with T2DM or obesity, with efficacy increasing at higher doses.

If you have T2DM or obesity, the 45 mg dose of oral orforglipron is highly effective for reducing weight and blood sugar. It works by mimicking a gut hormone to control appetite and insulin. Expect significant results, but be aware of potential side effects like nausea.

Combined treatment with structured moderate-to-vigorous exercise and GLP-1 receptor agonist (liraglutide) significantly improves physical functional performance and cardiorespiratory fitness compared to pharmacotherapy alone, whereas pharmacotherapy alone fails to improve these fitness metrics despite weight loss.

If you are using GLP-1 medication for weight loss, do not skip exercise. The medication will help you lose weight, but it will not significantly improve your stamina or physical function. To improve your ability to perform daily tasks (like climbing stairs) and your heart health, you must engage in structured moderate-to-vigorous exercise (at least 150 minutes per week). Combining the medication with exercise yields the best results for physical fitness.

Exercise alone produces similar improvements in physical functional performance and cardiorespiratory fitness as the combined treatment of exercise and GLP-1 agonist, indicating that exercise is the primary driver of fitness gains independent of the pharmacotherapy.

You do not need to take medication to get the physical fitness benefits of exercise. A structured exercise program (150+ minutes of moderate-to-vigorous activity per week) improves your stamina and functional performance just as well as combining exercise with GLP-1 medication. If you cannot or choose not to take medication, exercise remains the most effective way to improve physical fitness.

Next-generation GLP-1 based therapies (oral formulations, small-molecule agonists, multi-receptor agonists) aim to achieve greater efficacy (>25% weight loss), improved tolerability, and novel delivery platforms.

Next-generation GLP-1 based therapies aim to achieve greater weight loss (>25%), improved tolerability, and novel delivery platforms, including oral formulations and small-molecule agonists. These therapies are currently in clinical trials and represent the future direction of obesity treatment.

GLP-1 receptor agonists (liraglutide 3 mg, semaglutide 2.4 mg) and tirzepatide are effective first-line pharmacological treatments for obesity in psoriasis patients, providing significant weight loss and independent improvements in psoriasis severity (PASI scores) through anti-inflammatory mechanisms.

If you have psoriasis and obesity, GLP-1 drugs like semaglutide or tirzepatide are highly effective first-line treatments. They help you lose significant weight and can directly reduce your psoriasis severity, not just through weight loss but by lowering inflammation. Start with lifestyle changes, but if you need medication, these drugs are safe and effective. Work with your doctor to find the right dose and manage any initial stomach side effects by starting low and going slow.

GLP-1 agonist semaglutide produces significant weight loss (12.7%) and improves cardiometabolic risk in adults with obesity, with transient mild-to-moderate nausea and diarrhea as primary side effects.

If you have obesity and meet the criteria (BMI ≥30 or ≥27 with complications), discuss GLP-1 agonists like semaglutide with your doctor. This medication can lead to substantial weight loss (around 12.7% in studies) and improves blood sugar and heart disease risk. Common side effects like nausea or diarrhea are usually temporary and manageable.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) produce significant weight loss (6.2–15.8 kg) in adults with obesity, with efficacy increasing with higher doses.

GLP-1 agonists like semaglutide and liraglutide are effective for significant weight loss in adults with obesity, often outperforming lifestyle changes alone. Expect weight loss between 6-16 kg over several months. Be aware of gastrointestinal side effects, which are common but often manageable. These are prescription medications requiring medical supervision to manage dosing and side effects.

Semaglutide (2.4 mg weekly) produces significant weight loss (10-15%) in adults with obesity by slowing gastric emptying and reducing appetite, but discontinuation leads to substantial weight regain, necessitating continuous treatment.

Semaglutide 2.4mg weekly is a highly effective tool for significant weight loss (10-15%) in obesity, working by reducing appetite and slowing digestion. However, it is not a cure; stopping the medication typically leads to regaining most of the lost weight. It works best when combined with lifestyle changes and requires ongoing medical supervision to manage side effects like nausea and to ensure long-term success.

Semaglutide 2.4 mg administered once weekly produces significant weight loss (mean 14.9%) in adults with obesity or overweight, superior to placebo, when combined with lifestyle interventions.

Semaglutide 2.4mg weekly, combined with diet and exercise, leads to substantial weight loss (approx 15%) in obese adults without diabetes. Expect potential nausea, which often subsides. It is more effective than older drugs like orlistat and requires weekly injection rather than daily.

Discontinuation of semaglutide leads to partial weight regain, indicating that continuous treatment is necessary to maintain weight loss results.

If you stop taking semaglutide, you will likely regain some of the weight you lost. Long-term maintenance usually requires continuing the treatment.

GLP-1 receptor agonists (GLP1RAs) such as semaglutide and liraglutide induce significant weight loss (5-15%) and improve metabolic markers by delaying gastric emptying, suppressing appetite via central nervous system signaling, and enhancing glucose-dependent insulin secretion.

GLP-1 medications like semaglutide and liraglutide are highly effective for weight loss (5-22%) and metabolic health. They work by slowing digestion and signaling fullness to the brain. Start with the lowest dose to minimize nausea, which usually improves over time. Combine with a calorie-controlled diet and exercise for best results. Oral versions exist but may have different absorption requirements.

GLP-1 analogues (liraglutide, semaglutide, tirzepatide, efpeglenatide) combined with lifestyle interventions produce significant weight loss (5-15%) and reduce cardiometabolic risk in adults with obesity.

GLP-1 medications like semaglutide and liraglutide are effective tools for weight loss when combined with diet and exercise. They work by slowing digestion and reducing appetite. While gastrointestinal side effects like nausea are common, they often subside. These drugs are approved for adults with high BMI or obesity-related comorbidities.

A daily caloric deficit of 500-1,000 kcal combined with personalized dietary composition (high fiber, low refined carbs) induces a sustainable weight loss of 2-4 kg per month while preserving muscle mass and basal metabolic rate.

To lose weight sustainably, create a daily deficit of 500 to 1,000 calories by eating slightly less and moving slightly more. Aim for 2-4 kg of loss per month. Prioritize whole grains, vegetables, and fiber while cutting refined carbs and sugary drinks. This moderate pace protects your muscle and metabolism, making it easier to keep the weight off long-term.

Administration of GLP-1 receptor agonists (semaglutide 2.4 mg weekly or liraglutide 3.0 mg daily) combined with lifestyle interventions significantly reduces body weight and modulates gut microbiota composition in adults with obesity.

If you have obesity, GLP-1 medications like semaglutide (2.4 mg weekly) or liraglutide (3.0 mg daily) are highly effective for weight loss when combined with lifestyle changes. They work by mimicking hormones that regulate blood sugar and gut health, leading to significant weight reduction and improved metabolic markers.